\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationBrussels
The next Science for health conference, jointly organised by Medvia and BioWin, will discuss how AI, data & digitalisation can accelerate innovation in drug discovery & development and prevention & diagnostics. With a wide range of speakers and case studies, focus will be on how these digital technologies can help revolutionising the healthcare of today and tomorrow.
The conference brings together academics, industry leaders and policymakers every year to tackle health challenges and spark new research collaborations. During past editions, over 300 people united to form connections in Belgium and beyond.
More information, the conference programme and registration on the event's website. Note that this is a paying event.
Background: The Science for health conference is organised jointly by Medvia and BioWin. Medvia is the innovation cluster of Flanders for better health. It facilitates & supports collaborations among healthtech companies. BioWin is the Health Cluster of Wallonia. It is the regional reference holder for all stakeholders in innovative R&I projects in health biotechnology and medical technologies.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health AI Continent Deployment: Best use of technologies
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
